Flag of the European Union EU Clinical Trials Register Help

Clinical trials for boehringer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    904 result(s) found for: boehringer. Displaying page 3 of 46.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2014-001259-22 Sponsor Protocol Number: 1160.105 Start Date*: 2014-08-05
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: open-label, single dose, tolerability, Pharmacokinetic/Pharmacodynamics and safety study of dabigatran etexilate given at the end of standard anticoagulant therapy in children aged less than 1 yea...
    Medical condition: venous thrombotic event
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004866 10066899 Venous thromboembolism LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed) IT (Prematurely Ended) FR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-005117-23 Sponsor Protocol Number: 1311.3 Start Date*: 2016-04-14
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: BI 655066/ABBV-066 (risankizumab) versus Ustekinumab and placebo comparators in a randomized double blind trIal for Maintenance use in Moderate to severe plaque type psoriasis (UltIMMa-1)
    Medical condition: Psoriasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2013-002114-12 Sponsor Protocol Number: 1160.106 Start Date*: 2013-09-20
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: Open-label, randomized, parallel-group, active-controlled, multi-centre, non-inferiority study of dabigatran etexilate versus standard of care for venous thromboembolism treatment in children from ...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10066899 Venous thromboembolism LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) LT (Completed) BE (Completed) ES (Completed) SE (Completed) FI (Completed) SK (Completed) GR (Completed) NO (Completed) IT (Completed) AT (Completed) BG (Completed) Outside EU/EEA FR (Completed) HU (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-001091-34 Sponsor Protocol Number: 1305-0014 Start Date*: 2022-12-19
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF)
    Medical condition: Idiopathic Pulmonary Fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) FR (Completed) ES (Ongoing) DE (Completed) NO (Completed) EE (Completed) FI (Completed) SI (Completed) PT (Completed) SE (Completed) NL (Completed) HU (Completed) BE (Completed) IT (Completed) GR (Completed) DK (Completed) HR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000261-21 Sponsor Protocol Number: 1399-0003 Start Date*: 2019-10-08
    Sponsor Name:Boehringer Ingelheim
    Full Title: A randomised, double-blind, placebo-controlled and parallel group trial to evaluate efficacy and safety of twice daily inhaled doses of BI 1265162 delivered by Respimat® inhaler as add-on therapy t...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) FR (Prematurely Ended) BE (Prematurely Ended) IE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003529-33 Sponsor Protocol Number: 1320.22 Start Date*: 2016-03-24
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A randomized, double-masked, placebo-controlled exploratory study to evaluate pharmacodynamics, safety and tolerability of orally administered BI 1026706 for 12 weeks in patients with mild visual i...
    Medical condition: Patients with mild visual impairment due to center-involved diabetic macular edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) GB (Completed) GR (Completed) ES (Completed) BE (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022685-27 Sponsor Protocol Number: 1160.113 Start Date*: 2011-09-02
    Sponsor Name:Boehringer Ingelheim AB
    Full Title: A Randomised, phase II study to Evaluate the sAfety and pharmacokinetics of oraL dabIGatran etexilate in patients after heart valve replacemeNt
    Medical condition: anticoagulation following mechanical heart valve surgery
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10053349 Pharmacokinetic study LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) NL (Completed) BE (Completed) NO (Completed) DK (Completed) DE (Prematurely Ended) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-002442-19 Sponsor Protocol Number: 502.480 Start Date*: 2005-08-31
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A prospective randomised study to compare a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 25 mg with a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12...
    Medical condition: essential hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) IE (Completed) DK (Completed) FI (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004567-30 Sponsor Protocol Number: 1313.20 Start Date*: 2014-04-15
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: A single arm open label study to evaluate the pharmacodynamics and safety of a 4 wk treatment with BI 144807 in patients with newly diagnosed wet age related macular degeneration (wAMD)
    Medical condition: patients with newly diagnosed, unilateral, wet Are-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004853 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003360-37 Sponsor Protocol Number: 1199.247 Start Date*: 2017-02-28
    Sponsor Name:Boehringer Ingelheim
    Full Title: A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
    Medical condition: The aim of the current study is to investigate the efficacy and safety of 150 mg bid nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) defined as pa...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) BE (Completed) DE (Completed) GB (Completed) PL (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002280-34 Sponsor Protocol Number: 1245.121 Start Date*: 2017-06-19
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fracti...
    Medical condition: Heart failure (HF) with reduced ejection fraction (EF).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) FR (Completed) ES (Completed) HU (Completed) CZ (Completed) BE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002902-29 Sponsor Protocol Number: 1311.6 Start Date*: 2014-01-09
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: A phase II, multicenter, randomized, double-blind, multiple dose, placebo-controlled, parallel-group study to evaluate the efficacy, pharmacokinetics, and safety of BI 655066, an IL-23 p19 antagoni...
    Medical condition: Crohn's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) IE (Completed) ES (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021415-16 Sponsor Protocol Number: 1200.67 Start Date*: 2011-09-14
    Sponsor Name:Boehringer Ingelheim
    Full Title: Randomised phase II study of afatinib alone or in combination with vinorelbine versus investigator’s choice of treatment in patients with HER2-positive breast cancer with progressive brain metastas...
    Medical condition: HER2 positive breast cancer with progressive brain metastases after trastuzumab or lapatinib based therapy
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FI (Completed) ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004158-24 Sponsor Protocol Number: 1218.83 Start Date*: 2012-01-26
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: A 24-week, randomized, double-blind, active-controlled, parallel group trial to assess the superiority of oral linagliptin and metformin compared to linagliptin monotherapy in newly diagnosed, trea...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2015-000640-42 Sponsor Protocol Number: 1199.222 Start Date*: 2015-08-26
    Sponsor Name:Boehringer Ingelheim France
    Full Title: A twelve week, open-label, randomised, parallel-group study evaluating safety, tolerability and pharmacokinetics (PK) of oral nintedanib in combination with oral pirfenidone, compared to treatment ...
    Medical condition: Idiopathic Pulmonary Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003078-28 Sponsor Protocol Number: 1368-0016 Start Date*: 2019-07-01
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: Multi-center, double-blind, randomised, placebo-controlled, phase IIb dose-finding study to evaluate efficacy and safety of different subcutaneous doses of BI 655130 in patients with moderate to ...
    Medical condition: Palmoplantar Pustulosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10050185 Palmoplantar pustulosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) FR (Completed) CZ (Completed) PL (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-003090-34 Sponsor Protocol Number: 1368-0008 Start Date*: 2019-02-05
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: Mechanism of Action and Clinical Effect of BI 655130 in Patients with fistulizing Crohn’s Disease
    Medical condition: Fistulizing Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10075465 Fistulizing Crohn's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) BE (Completed) DE (Completed) NL (Prematurely Ended) HU (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001673-93 Sponsor Protocol Number: 1368-0007 Start Date*: 2020-02-05
    Sponsor Name:Boehringer Ingelheim
    Full Title: An open label, long term safety trial of spesolimab treatment in patients with fistulising Crohn’s disease who have completed previous spesolimab trials
    Medical condition: Crohns disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10011408 Crohns disease aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) HU (Completed) BE (Completed) ES (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002380-24 Sponsor Protocol Number: 1200.125 Start Date*: 2012-02-22
    Sponsor Name:Boehringer Ingelheim España, S.A
    Full Title: LUX-Lung 8: A randomized, open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-...
    Medical condition: Squamous cell carcinoma of the lung requiring second-line therapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025126 Lung squamous cell carcinoma stage unspecified PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) PT (Completed) GR (Completed) DK (Completed) HU (Completed) IE (Completed) GB (Completed) AT (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-000074-23 Sponsor Protocol Number: 248.525 Start Date*: 2007-05-11
    Sponsor Name:Boehringer Ingelheim Limited
    Full Title: A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR ...
    Medical condition: Male or female patients, with idiopathic PD diagnosed for at least 2 years, 30 years of age or older at time of diagnosis, with a modified Hoehn and Yahr scale of 2 to 4 at on-time.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) IT (Completed) CZ (Completed) HU (Completed) AT (Completed) SK (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 21 08:13:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA